Thursday, July 02, 2020 11:27:16 AM
Recent XERS News
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics • Business Wire • 05/06/2024 11:00:00 AM
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 05/02/2024 11:00:00 AM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 08:05:00 PM
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/02/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:10:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:27:40 PM
- Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events • Business Wire • 03/06/2024 12:02:00 PM
- Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital • Business Wire • 03/06/2024 12:00:00 PM
- Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 • Business Wire • 02/28/2024 12:00:00 PM
- Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference • Business Wire • 02/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 10:05:28 PM
- Xeris Biopharma Shares Climb 12% on Amgen License Agreement • Dow Jones News • 01/10/2024 03:12:00 PM
- Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment • Dow Jones News • 01/10/2024 01:53:00 PM
- Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab • Business Wire • 01/10/2024 01:00:00 PM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 01/05/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:09:00 PM
- Xeris Biopharma Updates Its Outlook for 2023 • Business Wire • 01/04/2024 12:00:00 PM
- Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/27/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 09:16:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:20:00 PM
- Xeris Biopharma Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 11:12:06 AM
- Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023 • Business Wire • 10/16/2023 11:00:00 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM